Cognitive and functional changes associated with Aβ pathology and the progression to mild cognitive impairment

Neurobiology of Aging

Volumn 48, Issue , 2016, Pages 172-181

  Insel, Philip S ^a,b,c   Donohue, Michael C ^d   Mackin, R Scott ^b,e   Aisen, Paul S ^d   Hansson, Oskar ^a   Weiner, Michael W ^b,c   Mattsson, Niklas ^a  

^a LUND UNIVERSITY   (Sweden)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clinical trials; Cognition; Composite; Function; Mild cognitive impairment; amyloid

Indexed keywords

AMYLOID BETA PROTEIN;

AGED; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; BOSTON NAMING TEST; CATEGORY FLUENCY; CLINICAL DEMENTIA RATING; COGNITION; COGNITIVE FUNCTION TEST; CONTROLLED STUDY; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL ASSESSMENT QUESTIONNAIRE; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; REY AUDITORY VERBAL LEARNING TEST; TRAIL MAKING TEST; WECHSLER MEMORY SCALE; COGNITIVE DEFECT; COHORT ANALYSIS; DISEASE COURSE; METABOLISM; PATHOLOGY; PSYCHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; COGNITION; COGNITIVE DYSFUNCTION; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE;

EID: 84991609096     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2016.08.017     Document Type: Article

References (37)

1. Ard, M.C., Raghavan, N., Edland, S.D., Optimal composite scores for longitudinal clinical trials under the linear mixed effects model. Pharm. Stat. 14 (2015), 418–426.
2. Ayutyanont, N., Langbaum, J.B., Hendrix, S.B., Chen, K., Fleisher, A.S., Friesenhahn, M., The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers. J. Clin. Psychiatry 75 (2014), 652–660.
3. Breiman, L., Bagging predictors. Machine Learn. 24 (1996), 123–140.
4. Breiman, L., Random forests. Machine Learn. 45 (2001), 5–32.
5. Byrd, R.H., Lu, P., Nocedal, J., Zhu, C., A limited memory algorithm for bound constrained optimization. SIAM J. Scientific Comput. 16 (1995), 1190–1208.
6. Chambers, J.M., Hastie, T.J., Statistical Models in S. 1992, Wadsworth & Brooks/Cole.
7. Donohue, M.C., Sperling, R.A., Salmon, D.P., Rentz, D.M., Raman, R., Thomas, R.G., Weiner, M., Aisen, P.S., The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 71 (2014), 961–970.
8. Ellis, K.A., Bush, A.I., Darby, D., De Fazio, D., Foster, J., Hudson, P., Lautenschlager, N.T., Lenzo, N., Martins, R.N., Maruff, P., Masters, C., The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int. Psychogeriatrics 21 (2009), 672–687.
9. Hendrix, S.B., Measuring clinical progression in MCI and pre-MCI populations: enrichment and optimizing clinical outcomes over time. Alzheimers Res. Ther., 4, 2012, 24.
10. Hochberg, Y., A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75 (1988), 800–802.
11. Insel, P., Mattsson, N., Donohue, M.C., Mackin, S., Aisen, P., Jack, C., Shaw, L.M., Trojanowski, J.Q., Weiner, M.W., The transitional association between beta-amyloid pathology and regional brain atrophy. Alzheimers Demen. 10 (2014), P837–P838.
12. Insel, P.S., Mattsson, N., Mackin, R.S., Kornak, J., Nosheny, R., Tosun-Turgut, D., Donohue, M.C., Aisen, P.S., Weiner, M.W., Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease. Ann. Clin. Transl. Neurol. 2 (2015), 534–547.
13. Kaplan, E.F., Goodglass, H., Weintraub, S., The Boston Naming Test. second ed., 1982, Lea & Febiger, Philadelphia.
14. Kozauer, N., Katz, R., Regulatory innovation and drug development for early-stage Alzheimer's disease. N. Engl. J. Med. 368 (2013), 1169–1171.
15. Landau, S.M., Mintun, M.A., Joshi, A.D., Koeppe, R.A., Petersen, R.C., Aisen, P.S., Weiner, M.W., Jagust, W.J., Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann. Neurol. 72 (2012), 578–586.
16. Langbaum, J.B., Hendrix, S.B., Ayutyanont, N., Chen, K., Fleisher, A.S., Shah, R.C., Barnes, L.L., Bennett, D.A., Tariot, P.N., Reiman, E.M., An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease. Alzheimers Demen. 10 (2014), 666–674.
17. Mattsson, N., Insel, P.S., Donohue, M., Landau, S., Jagust, W.J., Shaw, L.M., Trojanowski, J.Q., Zetterberg, H., Blennow, K., Weiner, M.W., Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease. Brain 138 (2015), 772–783.
18. Mattsson, N., Insel, P.S., Nosheny, R., Tosun, D., Trojanowski, J.Q., Shaw, L.M., Jack, C.R., Donohue, M.C., Weiner, M.W., Emerging β-amyloid pathology and accelerated cortical atrophy. JAMA Neurol. 71 (2014), 725–734.
19. McKhann, G.M., Knopman, D.S., Chertkow, H., Hyman, B.T., Jack, C.R., Kawas, C.H., Klunk, W.E., Koroshetz, W.J., Manly, J.J., Mayeux, R., Mohs, R.C., The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Demen. 7 (2011), 263–269.
20. Morris, J.C., The clinical dementia rating (CDR): current version and scoring rules. Neurology 43 (1993), 2412–2414.
21. Morris, J.C., Early-stage and preclinical Alzheimer disease. Alzheimer Dis. Assoc. Disord. 19 (2005), 163–165.
22. Olsson, A., Vanderstichele, H., Andreasen, N., De Meyer, G., Wallin, A., Holmberg, B., Rosengren, L., VanMechelen, E., Blennow, K., Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin. Chem. 51 (2005), 336–345.
23. Pfeffer, R.I., Kurosaki, T.T., Harrah, C.H. Jr., Chance, J.M., Filos, S., Measurement of functional activities in older adults in the community. J. Gerontol. 37 (1982), 323–329.
24. Raghavan, N., Samtani, M.N., Farnum, M., Yang, E., Novak, G., Grundman, M., Narayan, V., DiBernardo, A., The ADAS-Cog revisited: novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials. Alzheimers Demen. 9 (2013), S21–S31.
25. Reitan, R.M., Validity of the trail making test as an indicator of organic brain damage. Perceptual Mot. Skills 8 (1958), 271–276.
26. Rey, A., L'examen clinique en psychologie. 1964, Presses Universitaires De France, Paris.
27. Rosen, W.G., Mohs, R.C., Davis, K.L., A new rating scale for Alzheimer's disease. Am. J. Psychiatry 141 (1984), 1356–1364.
28. Shaw, L.M., Vanderstichele, H., Knapik-Czajka, M., Clark, C.M., Aisen, P.S., Petersen, R.C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., Dean, R., Cerebrospinal fluid biomarker signature in Alzheimer's Disease Neuroimaging Initiative subjects. Ann. Neurol. 65 (2009), 403–413.
29. Siddiqui, O., Hung, H.J., O'Neill, R., MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets. J. Biopharm. Stat. 19 (2009), 227–246.
30. Snyder, P.J., Kahle-Wrobleski, K., Brannan, S., Miller, D.S., Schindler, R.J., DeSanti, S., Ryan, J.M., Morrison, G., Grundman, M., Chandler, J., Caselli, R.J., Assessing cognition and function in Alzheimer's disease clinical trials: do we have the right tools?. Alzheimers Demen. 10 (2014), 853–860.
31. Sperling, R.A., Aisen, P.S., Beckett, L.A., Bennett, D.A., Craft, S., Fagan, A.M., Iwatsubo, T., Jack, C.R., Kaye, J., Montine, T.J., Park, D.C., Toward defining the preclinical stages of Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Demen. 7 (2011), 280–292.
32. Sperling, R.A., Jack, C.R. Jr., Aisen, P.S., Testing the right target and right drug at the right stage. Sci. Transl. Med., 3, 2011, 111cm33.
33. Sperling, R.A., Rentz, D.M., Johnson, K.A., Karlawish, J., Donohue, M., Salmon, D.P., Aisen, P., The A4 study: stopping AD before symptoms begin?. Sci. Transl. Med., 6, 2014, 228fs13.
34. US Dept of Health and Human Services; US Food and Drug Administration; Center for Drug Evaluation and Research. Guidance for industry: Alzheimer's disease: developing drugs for the treatment of early stage disease (draft guidance). Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM338287.pdf. Accessed August 8, 2015.
35. Vos, S.J., Xiong, C., Visser, P.J., Jasielec, M.S., Hassenstab, J., Grant, E.A., Cairns, N.J., Morris, J.C., Holtzman, D.M., Fagan, A.M., Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol. 12 (2013), 957–965.
36. Wang, J., Logovinsky, V., Hendrix, S.B., Stanworth, S.H., Perdomo, C., Xu, L., Dhadda, S., Do, I., Rabe, M., Luthman, J., Cummings, J., ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials. J. Neurol. Neurosurg. Psychiatry 87 (2016), 993–999.
37. Wechsler, D.A., Wechsler Adult Intelligence Scale–Revised. 1987, Psychological Corporation, New York.